Zepbound vs Wegovy for Women: Which Is Better for Menopause Weight?

If you are in your late forties or early fifties and the scale has quietly crept up despite eating the same way you always have, you are not imagining things. The hormonal shifts of perimenopause and menopause change where your body stores fat, how hungry you feel, and how efficiently you burn calories. So when two of the most effective weight medications ever studied, Zepbound and Wegovy, are sitting in front of you, the question is reasonable and very specific: for a woman navigating menopause weight, which one is actually better? This guide walks through the science, the side effects, the real 2026 costs, and the menopause angle most generic comparisons skip, so you can have a focused conversation with a prescriber.

Quick orientation before we dive in. Zepbound is the brand name for tirzepatide, made by Eli Lilly. Wegovy is the brand name for semaglutide, made by Novo Nordisk. Both are once-weekly injections approved by the FDA for chronic weight management, both require a prescription and eligibility (typically a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure or sleep apnea), and both work best alongside changes to food, movement, and sleep. They are tools, not magic, and they are not interchangeable.

How they work: one target versus two

This is where the two drugs genuinely differ, and the difference matters. Semaglutide (Wegovy) is a GLP-1 receptor agonist. It mimics one gut hormone, GLP-1, that tells your brain you are full, slows how fast your stomach empties, and helps steady blood sugar. Tirzepatide (Zepbound) is a dual agonist. It activates the GLP-1 receptor and a second one called GIP. The leading theory is that adding the GIP pathway improves how the body handles fat and energy and may even soften some of the nausea that comes from GLP-1 alone.

In plain terms: Wegovy pulls one lever, Zepbound pulls two. That mechanical difference shows up clearly in the head-to-head data, which is unusual and valuable. Most weight drugs are only ever compared to placebo. These two were tested directly against each other.

The head-to-head results: what SURMOUNT-5 found

The SURMOUNT-5 trial, with full results published in The New England Journal of Medicine, randomly assigned 751 adults with obesity (mean age 45, squarely in the menopause-transition window) to the maximum tolerated dose of either tirzepatide or semaglutide for 72 weeks. The outcome was decisive.

• Average weight loss: about 20.2% of body weight on Zepbound versus 13.7% on Wegovy. In pounds, that worked out to roughly 50 pounds versus 33 pounds on average.
• Bigger results, more often: about 32% of Zepbound patients lost at least a quarter of their body weight, compared with roughly 16% on Wegovy. More than 64% of tirzepatide patients hit 15% loss or greater.
• Waist circumference: shrank by an average of about 18 cm on Zepbound versus 13 cm on Wegovy, which is relevant because menopause tends to redistribute fat to the midsection.

So on raw average effectiveness, tirzepatide (Zepbound) won, and it was not close. Eli Lilly summarized it as roughly 47% greater relative weight loss. That said, averages hide individuals. Plenty of women do beautifully on semaglutide and reach their goals, and a meaningful share of people respond better to one molecule than the other for reasons we cannot yet predict. "Statistically superior" is not the same as "the right one for you."

Side effects: more alike than different

Both medications share the same family of side effects, and for both, the most common ones are gastrointestinal: nausea, diarrhea, constipation, and occasional vomiting. These usually show up during dose escalation and tend to ease over the first 8 to 12 weeks as your body adjusts. Going slow on dose increases is the single best way to stay comfortable.

The head-to-head data suggests tirzepatide is tolerated slightly better, not worse, despite being more powerful. In SURMOUNT-5, discontinuation because of GI side effects was about 2.7% on tirzepatide versus 5.6% on semaglutide. Nausea rates ran a bit lower on tirzepatide in several comparisons, which fits the GIP-buffering theory. Both carry a boxed warning about a rare risk of thyroid C-cell tumors seen in rodent studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis, gallbladder problems, and dehydration are uncommon but real risks for both. This is exactly the kind of history a licensed clinician needs to screen before prescribing.

One honest caveat for menopausal women specifically: rapid weight loss of any kind can accelerate loss of muscle and bone, and bone density is already a concern after estrogen declines. Prioritizing protein and resistance training while on either drug is not optional advice, it is central to doing this safely. The Endocrine Society and Mayo Clinic both emphasize muscle preservation during GLP-1 therapy.

Cost in 2026: closer than the headlines suggest

Pricing is where the decision often actually gets made, and it has shifted fast. As of 2026, both manufacturers run cash-pay programs that bypass the eye-watering retail list prices (which hovered around $1,000 to $1,350 a month). Please treat the figures below as a snapshot and confirm current numbers on each company's own site, because these programs change often.

With commercial insurance that covers obesity treatment, copays can drop to as little as $25 a month for either drug, but coverage for weight loss (as opposed to diabetes) remains spotty. Medicare does not cover either drug purely for weight loss, though it may cover them when prescribed for an approved condition like cardiovascular risk reduction. For a fuller picture of paying out of pocket, our guide to treatment without insurance and the 2026 cost breakdown are good companions. The bottom line on price: the two are far closer than they used to be, so cost is now rarely the deciding factor by itself.

A word on compounded versions

You may have seen telehealth ads for cheaper "compounded" semaglutide or tirzepatide. The regulatory landscape changed significantly. The FDA declared the semaglutide and (initially) tirzepatide shortages resolved, and by 2025 it had removed these drugs from the lists that allowed large-scale compounding. Compounding under valid patient-specific prescriptions through licensed 503A pharmacies still exists in certain situations, but the era of cheap, widely available compounded GLP-1s is closing, and the legal status is genuinely in flux. The FDA has logged hundreds of adverse-event reports tied to compounded products, many from dosing errors. Never buy "research-grade" peptides or anything from a seller that does not require a prescription and a licensed clinician. If compounding comes up, read our current compounded semaglutide 2026 update and verify legality where you live before committing.

The menopause angle: why this is not just a generic drug comparison

Here is the part most Zepbound-versus-Wegovy articles miss entirely. If your weight gain is tied to the menopause transition, the drug you choose is only half the equation. The other half is your hormones.

When estrogen falls, several things conspire against you. Fat redistributes to the abdomen, metabolism slows, sleep fragments (and poor sleep drives hunger hormones the wrong way), and emerging research suggests your body's own GLP-1 production may dip, because estradiol appears to help stimulate GLP-1 secretion in the first place. That is a striking idea: the very hormone that fades in menopause is connected to the same pathway these drugs target.

This is why the combination research is so interesting. A 2024 study in the journal Menopause found postmenopausal women on semaglutide plus hormone therapy lost more weight than those on semaglutide alone, and a 2026 Mayo Clinic analysis reported women on tirzepatide plus HRT lost meaningfully more than tirzepatide alone. Both were observational, not randomized controlled trials, so the findings should be read as promising rather than proven, and randomized trials are underway. But the biological logic (estrogen improving the metabolic environment in which a GLP-1 works) is sound and consistent. We cover the details in our GLP-1 and HRT combination guide and the specific tirzepatide and HRT evidence, with the broader picture in our 2026 weight-loss research roundup.

The practical takeaway: if your symptoms include hot flashes, sleep disruption, and stubborn midlife weight gain all at once, do not treat the weight in isolation. Ask your clinician whether addressing the hormonal picture alongside a GLP-1 makes sense for you. The two strategies may reinforce each other.

So which should you pick?

If your single priority is maximum average weight loss and you tolerate it, the evidence currently points to Zepbound (tirzepatide). It produced more weight loss, more waist reduction, and slightly better tolerability in the only large head-to-head trial we have. It is the reasonable default to discuss first.

Wegovy (semaglutide) remains an excellent, well-established choice, and it makes sense if it is the one your insurance covers, if your prescriber has more experience with it, if you want the option of an oral form, or if it is simply more available to you. It also has the longer track record and dedicated cardiovascular-benefit data. "Slightly less on average" still means very effective for most women.

And to be balanced: neither drug is right for everyone. If your BMI does not meet eligibility, if you have a history of medullary thyroid cancer, pancreatitis, or certain GI conditions, if you are pregnant or planning pregnancy, or if you are unwilling to commit to the lifestyle and muscle-preserving habits that make results stick, this category may not be your best path right now. These are long-term medications; weight tends to return when they stop. That is not a flaw, it is how chronic-condition treatment works, but it should shape your expectations.

Your next step: you will need a prescriber

You cannot get either medication without a licensed clinician confirming you are eligible and screening your history, and that is a feature, not a hurdle. A good prescriber will help you weigh the two drugs, escalate the dose safely, and decide whether the menopause-hormone piece belongs in your plan.

If you want a telehealth route focused on GLP-1 care, Henry Meds is a commonly used option, and Hers offers weight care alongside broader women's health services, which can be convenient if you also want to discuss menopause symptoms in one place. To see how providers stack up side by side, our treatment comparison tool and our guide to getting these medications in menopause are the best places to start. Browse the full provider directory if you want to keep your options open. Whatever you choose, walk in with your questions written down and let the data, not the marketing, lead the conversation.

"Zepbound won the head-to-head on average weight loss, but the better question for a woman in menopause is not just which drug, it is whether your hormones belong in the plan too."

FindMyHRT is an independent directory. Some links to providers are partnerships and we may earn a commission at no extra cost to you. Partners we can earn from may be shown first in some lists, but commission does not affect whether a provider is listed or the facts we report about them. See our Affiliate Disclosure.

Medical Disclaimer: This article is for general educational purposes only and is not medical advice. Hormone therapy, GLP-1 medications, and menopause treatment decisions are individual and should be made with a qualified healthcare provider who knows your full history. Prescription medications require evaluation by a licensed clinician. Always consult your provider before starting or changing any treatment.